SC 13G/A

Names of Reporting Persons

Apeiron Investment Group Ltd.

Check the Appropriate Box if a Member of a Group

(a) ☐ (b) ☐

SEC Use Only

Citizenship or Place of Organization

Malta

SC 13G/A 1 d787948dsc13ga.htm SC 13G/A SC 13G/A

Securities and Exchange Commission

Washington, D.C. 20549

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

ATAI Life Sciences N.V.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

N0731H103

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. N0731H103		Schedule 13G		Page 1 of 10


Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0
	6	Shared Voting Power 33,885,999
	7	Sole Dispositive Power 0
	8	Shared Dispositive Power 33,885,999


CUSIP No. N0731H103		Schedule 13G		Page 2 of 10


Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0
	6	Shared Voting Power 1,799,302
	7	Sole Dispositive Power 0
	8	Shared Dispositive Power 1,799,302


CUSIP No. N0731H103		Schedule 13G		Page 3 of 10


Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0
	6	Shared Voting Power 1,799,302
	7	Sole Dispositive Power 0
	8	Shared Dispositive Power 1,799,302


CUSIP No. N0731H103		Schedule 13G		Page 4 of 10


Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0
	6	Shared Voting Power 1,799,302
	7	Sole Dispositive Power 0
	8	Shared Dispositive Power 1,799,302


CUSIP No. N0731H103		Schedule 13G		Page 5 of 10


Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 0
	6	Shared Voting Power 33,885,999
	7	Sole Dispositive Power 0
	8	Shared Dispositive Power 33,885,999


CUSIP No. N0731H103		Schedule 13G		Page 6 of 10


ITEM 1.	(a)	Name of Issuer:

		ATAI Life Sciences N.V. (the “Issuer”).

	(b)	Address of Issuer’s Principal Executive Offices:

		ATAI Life Sciences N.V., Wallstraße 16, 10179, Berlin, Germany.

ITEM 2.	(a)	Name of Person Filing:

		Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

		Apeiron Investment Group Ltd. (“Apeiron”);
		Apeiron Presight Capital Fund II, L.P. (“Presight II”);
		Presight Capital Management I, L.L.C. (“Presight Management”);
		Fabian Hansen; and
		Christian Angermayer.

	(b)	Address or Principal Business Office:

		The principal business address of Apeiron and Mr. Angermayer is 66 & 67 Amery Street, SLM1707, Sliema, Malta. The principal business address of each of the remaining Reporting Persons is 440 N Barranca Ave #3391 Covina, CA 91723 USA.

	(c)	Citizenship of each Reporting Person is:

		Presight II and Presight Management are organized under the laws of the State of Delaware. Apeiron is organized under the laws of Malta. Each of Messrs. Hansen and Angermayer is a German citizen.

	(d)	Title of Class of Securities:

		Common shares, par value €0.1 per share (“Common Shares”).

	(e)	CUSIP Number:

		N0731H103

ITEM 3.

	Not applicable.


CUSIP No. N0731H103		Schedule 13G		Page7 of 10


ITEM 4.		Ownership.

		(a-c)

		The ownership information presented below represents beneficial ownership of the Common Shares of the Issuer as of December 31, 2023, based upon 166,010,476 shares of Common Shares outstanding as of November 6, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2023.


Reporting Person	Amount beneficially owned		Percent of class:			Sole power to vote or to direct the vote:		Shared power to vote or to direct the vote:		Sole power to dispose or to direct the disposition of:		Shared power to dispose or to direct the disposition of:
Apeiron Investment Group Ltd.		33,885,999		20.1	%		0		33,885,999		0		33,885,999
Apeiron Presight Capital Fund II, L.P.		1,799,302		1.1	%		0		1,799,302		0		1,799,302
Presight Capital Management I, L.L.C.		1,799,302		1.1	%		0		1,799,302		0		1,799,302
Fabian Hansen		1,799,302		1.1	%		0		1,799,302		0		1,799,302
Christian Angermayer		33,885,999		20.1	%		0		33,885,999		0		33,885,999


		Presight II is the record holder of 1,799,302 Common Shares. Apeiron and Fabian Hansen are the managing members of Presight Management, which is the general partner of Presight II. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities held by Presight II.

		In addition, Apeiron is the record holder of 29,719,497 Common Shares and may be deemed to own an additional 2,367,200 Common Shares underlying convertible notes of the Issuer. Christian Angermayer is the majority shareholder of Apeiron and may be deemed to share beneficial ownership of the securities beneficially owned by Apeiron.

ITEM 5.		Ownership of Five Percent or Less of a Class.

		Not applicable.

ITEM 6.		Ownership of More than Five Percent on Behalf of Another Person.

		Not applicable.

ITEM 7.		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

		Not applicable.


CUSIP No. N0731H103		Schedule 13G		Page 8 of 10


ITEM 8.		Identification and Classification of Members of the Group.

		Not applicable.

ITEM 9.		Notice of Dissolution of Group.

		Not applicable.

ITEM 10.		Certification.

		Not applicable.


CUSIP No. N0731H103		Schedule 13G		Page 9 of 10

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2024



Apeiron Investment Group, Ltd.

By:		/s/ Julien Höfer
Name:		Julien Höfer
Title:		Director

Apeiron Presight Capital Fund II, L.P.

By:		Presight Capital Management I, L.L.C., its general partner

By:		/s/ Fabian Hansen
Name:		Fabian Hansen
Title:		Managing Member

Presight Capital Management I, L.L.C.

By:		/s/ Fabian Hansen
Name:		Fabian Hansen
Title:		Managing Member

Fabian Hansen

/s/ Fabian Hansen

Christian Angermayer

/s/ Christian Angermayer


CUSIP No. N0731H103		Schedule 13G		Page 10 of 10

LIST OF EXHIBITS

SEC Form SC 13G/A filed by ATAI Life Sciences N.V. (Amendment)